All In Biotech

Drug Trial Radar · NCT04314544

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

508

Actual

Start

Jul 1, 2020

Primary completion

Mar 26, 2025

Study completion Dec 22, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

Conditions

  • Active Psoriatic Arthritis

Interventions

  • TILDDrug

    one 1 mL injection of study medication

  • matching placebo injectionsDrug

    one 1 mL injection of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieve American College of Rheumatology [ACR20]Time frame: at week 24

Locations

97 sites in 12 countries. Site status is shown where the registry gives one.

  • Sunpharma Site no 42

    Dothan, Alabama

  • Sunpharma Site no 29

    Gilbert, Arizona

  • Sunpharma Site no 30

    Glendale, Arizona

  • Sunpharma Site no 31

    Mesa, Arizona

  • Sunpharma Site no 35

    Covina, California

  • Sunpharma Site no 48

    Encino, California

  • Sunpharma site no. 17

    Fountain Valley, California

  • Sunpharma site no. 15

    Thousand Oaks, California

  • Sunpharma Site no. 141

    Avon Park, Florida

  • Sunpharma site no. 21

    Clearwater, Florida

  • Sunpharma site no. 02

    Hialeah, Florida

  • Sunpharma Site no 55

    Kissimmee, Florida

  • Sunpharma Site no. 75

    Margate, Florida

  • Sunpharma site no. 05

    New Port Richey, Florida

  • Sunpharma Site no. 76

    Ocoee, Florida

  • SunPharma Site no 22

    Tamarac, Florida

  • Sunpharma Site no 46

    Gainesville, Georgia

  • Sunpharma Site no 41

    Oak Brook, Illinois

  • Sunpharma Site no 54

    Orland Park, Illinois

  • Sunpharma Site no 38

    Schaumburg, Illinois

  • Sunpharma Site no 37

    Skokie, Illinois

  • Sunpharma Site no. 122

    Skokie, Illinois

  • Sunpharma site no. 20

    Wichita, Kansas

  • Sunpharma site no. 07

    Worcester, Massachusetts

  • Sunpharma site no. 14

    Springfield, Missouri

  • Sunpharma Site no 53

    Kalispell, Montana

  • Sunpharma Site no 27

    Lincoln, Nebraska

  • Sunpharma Site no 44

    Voorhees Township, New Jersey

  • Sunpharma Site no 52

    Charlotte, North Carolina

  • Sunpharma Site no. 73

    Leland, North Carolina

  • Sunpharma Site no 56

    Wilmington, North Carolina

  • Sunpharma Site no 33

    Minot, North Dakota

  • Sunpharma site no. 11

    Middleburg Heights, Ohio

  • Sunpharma Site no. 124

    Oklahoma City, Oklahoma

  • Sunpharma Site no 34

    Greenville, South Carolina

  • Sunpharma Site no 50

    Austin, Texas

  • Sunpharma site no. 13

    Baytown, Texas

  • Sunpharma Site no 49

    Colleyville, Texas

  • Sunpharma site no. 08

    Houston, Texas

  • Sunpharma Site no 28

    Lubbock, Texas

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.